Dehydrocorydaline chloride

• CAT Number: I000306
• CAS Number: 10605-03-5
• Molecular Formula: C22H24ClNO4
• Molecular Weight: 401.88
• Purity: ≥95%
• Target: Cell Cycle/DNA Damage
• Solubility: DMSO
• Storage: store at-20℃
• IUPAC Name: 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride
• InChI: 1S/C22H24NO4.ClH/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23;/h6-7,10-12H,8-9H2,1-5H3;1H/q+1;/p-1
• InChIKey: WXOSEFNJXIPZNV-UHFFFAOYSA-M
• SMILES: CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC.[Cl-]

Dehydrocorydaline chloride (CAT: I000306) is an alkaloid compound with demonstrated anti-inflammatory and anti-cancer activities. In vitro, studies have shown that Dehydrocorydaline chloride promotes myoblast differentiation by increasing the expression of muscle-specific proteins and activating p38 MAPK signaling. It also exhibits anti-proliferative effects on MCF-7 breast cancer cells by inducing apoptosis through modulation of the Bax/Bcl-2 pathway and activation of caspases. In vivo, Dehydrocorydaline chloride demonstrates dose-dependent antinociceptive effects in pain models, reducing the expression of pro-inflammatory proteins in the spinal cord. These findings suggest the potential pharmacological applications of Dehydrocorydaline chloride in muscle regeneration, cancer therapy, and pain management.